Neubase TherapeuticsNBSE
13F holders, Q2 2024 (June 30)2holders −16
1new positions
18sold out
$0.31avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Neubase Therapeutics Inc. (NBSE) in their 13F filings, down 16 from Q1 2024. 1 opened new positions and 18 sold out. The largest holders were Baader Bank Aktiengesellschaft ($5K) and Osaic Holdings, Inc. ($0).
- Company
- Neubase Therapeutics Inc.
- CUSIP
- 64132K201
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $5K |
| Exits | 18 | $177K |
All 13F filers, Q1 2024 → Q2 2024: 16,089 shares bought and 393,393 shares sold, net −377,304 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Baader Bank Aktiengesellschaft | 0.00% | New | 16,089 | $5K |
| Osaic Holdings, Inc. | 0.00% | Reduce -95.5% | 1 | $0 |
"% of holder's portfolio" is NBSE's weight in each manager's 13F, not the share of Neubase Therapeutics Inc. the manager owns.